Regulatory effect of miR-1290 targeting IRF2 on proliferation and invasion of non-small cell lung cancer cells and its related mechanism

董　磊; 张仲妍

doi:10.19401/j.cnki.1007-3639.2020.01.004

您当前的位置：

首页 >

文章列表页 >

Regulatory effect of miR-1290 targeting IRF2 on proliferation and invasion of non-small cell lung cancer cells and its related mechanism

更新时间：2026-01-27

- Regulatory effect of miR-1290 targeting IRF2 on proliferation and invasion of non-small cell lung cancer cells and its related mechanism
- China Oncology Vol. 30, Issue 1, Pages: 32-40(2020)
- 作者机构：
  
  1. 武汉市红十字会医院肿瘤科,湖北,武汉,430000
  2. 重庆大学附属肿瘤医院中医肿瘤科,重庆,400030
- 作者简介：
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2020.01.004
  CLC： R734.2
- Published Online：17 January 2020，
  
  Published：17 January 2020
- 稿件说明：
移动端阅览
董　磊, 张仲妍 . 靶向IRF2的miR-1290对非小细胞肺癌细胞增殖、侵袭的调控作用及其机制研究[J]. 中国癌症杂志, 2020, 30(1): 32-40.

董　磊, 张仲妍. Regulatory effect of miR-1290 targeting IRF2 on proliferation and invasion of non-small cell lung cancer cells and its related mechanism[J]. China Oncology, 2020, 30(1): 32-40.
董　磊, 张仲妍 . 靶向IRF2的miR-1290对非小细胞肺癌细胞增殖、侵袭的调控作用及其机制研究[J]. 中国癌症杂志, 2020, 30(1): 32-40. DOI： 10.19401/j.cnki.1007-3639.2020.01.004.

董　磊, 张仲妍. Regulatory effect of miR-1290 targeting IRF2 on proliferation and invasion of non-small cell lung cancer cells and its related mechanism[J]. China Oncology, 2020, 30(1): 32-40. DOI： 10.19401/j.cnki.1007-3639.2020.01.004.

摘要

背景与目的：miR-1290可以调节干扰素调节因子-2（interferon regulatory factor-2，IRF2）的表达，调节非小细胞肺癌（non-small cell lung cancer，NSCLC）的恶性生物学行为，但其具体作用机制目前尚不清楚，因此，探讨miR-1290靶向IRF2对NSCLC细胞增殖、侵袭的调控作用及相关机制。方法：将体外培养的A549细胞分为miR-1290 mimic组、miR-1290 inhibitor组和NC组；实时荧光定量聚合酶链反应（real-time fluorescence quantitative polymerase chain reaction，RTFQ-PCR）和蛋白质印迹法（Western blot）检测各组细胞miR-1290和IRF2的表达，采用荧光素酶实验进一步验证靶向关系。将体外培养的A549细胞分为NC组（转染空白质粒）、miR-1290组（转染miR-1290）、IRF2组（转染IRF2）和miR-1290+IRF2组（转染miR-1290+IRF2）；细胞计数试剂盒（cell counting kit-8，CCK-8）检测各组细胞的增殖活性；Transwell实验检测各组细胞的侵袭，划痕实验检测细胞迁移，Western blot检测各组细胞血管内皮生长因子（vascular endothelial growth factor，VEGF）、E-钙黏着蛋白（E-cadherin）、基质金属蛋白酶（matrix metalloproteinase，MMP）-2和Ki-67。结果：miR-1290可以靶向负调控IRF2的表达；与NC组相比，miR-1290组miR-1290的表达明显上调（P0.05），IRF2的表达明显下调（P0.05），细胞增殖活性、侵袭力和迁移率明显上调（P0.05），VEGF、MMP-2和Ki-67明显上调（P0.05），E-cadherin水平明显下调（P0.05），IRF2组IRF2的表达明显上调（P0.05），细胞增殖活性、侵袭力和迁移率明显下调（P0.05），VEGF、MMP-2和Ki-67明显下调（P0.05），E-cadherin水平明显上调（P0.05）；与IRF2组相比，miR-1290+IRF2组miR-1290的表达明显上调（P0.05），IRF2的表达明显下调（P0.05），细胞增殖活性、侵袭力和迁移率明显上调（P0.05），VEGF、MMP-2和Ki-67明显上调（P0.05），E-cadherin水平明显下调（P0.05）。结论：miR-1290可能通过靶向负调控IRF2的表达，促进NSCLC细胞的增殖和侵袭。

Abstract

Background and purpose: miR-1290 can regulate the expression of interferon regulatory factor-2 (IRF2) and the malignant biological behavior of non-small cell lung cancer (NSCLC)

but the specific mechanism of its action is still unclear. Therefore

this study explored the regulatory effect of miR-1290 targeting IRF2 on the proliferation and invasion of NSCLC cells and its related mechanism. Methods: A549 cells cultured in vitro were divided into miR-1290 mimic group

miR-1290 inhibitor group and NC group. Real-time fluorescence quantitative polymerase chain reaction (RTFQ-PCR) and Western blot were performed to detect expression of miR-1290 and IRF2 in each group. Their targeted relationship was further verified by fluorescence assay. A549 cells cultured in vitro were divided into NC group (transfected with mimic)

miR-1290 group (transfected with miR-1290)

IRF2 group (transfected with IRF2) and miR-1290+IRF2 group (transfected with miR-1290+IRF2). Cell counting kit-8 (CCK-8) was performed to detect cell proliferation activity in each group. Transwell assay was performed to detect cell invasion in each group. The cell migration was detected by scratch test. The levels of vascular endothelial growth factor (VEGF)

E-cadherin

matrix metalloproteinase (MMP)-2 and Ki-67 in each group were detected by Western blot. Results: IRF2 expression could be negatively regulated by miR-1290. Compared with NC group

miR-1290 expression was significantly up-regulated in miR-1290 group (P0.05)

while IRF2 expression was significantly down-regulated (P0.05). Moreover

cell proliferation activity

invasion ability and migration rate were significantly increased (P0.05)

levels of VEGF

MMP-2 and Ki-67 were significantly up-regulated (P0.05)

and expression of E-cadherin was significantly down-regulated (P0.05) in miR-1290 group. IRF2 expression was significantly up-regulated in IRF2 group (P0.05)

cell proliferation activity

invasion ability and migration rate were significantly decreased (P0.05)

levels of VEGF

MMP-2 and Ki-67 were significantly down-regulated (P0.05)

and protein level of E-cadherin was significantly up-regulated (P0.05). Compared with IRF2 group

miR-1290 expression was significantly up-regulated in miR-1290+IRF2 group

while expression of IRF2 was significantly down-regulated (P0.05). In addition

cell proliferation activity

invasion ability and migration rate were significantly increased (P0.05)

levels of VEGF

MMP-2 and Ki-67 were significantly up-regulated (P0.05)

and protein level of E-cadherin was significantly down-regulated (P0.05). Conclusion: MiR-1290 may promote proliferation and invasion of NSCLC cells by negatively regulating IRF2 expression.

关键词

Keywords

references

Views

1833

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Research on high-throughput detection of plasma cell-free DNA for targeted therapy-related genes screening and prognosis prediction in non-small cell lung cancer patients

Clinical pathological characteristics and immune microenvironment significance of EGFR T790M mutation in non-small cell lung cancer patients and its prognostic implications

A study on prevention and treatment of chemotherapy induced nausea and vomiting in non-small cell lung cancer patients with low-frequency electrical stimulator for antiemesis

Important clinical research progress in lung cancer in 2022

Research progress of ALK kinase domain drug resistance mutation and its future countermeasures

Related Author

Qiling DENG

Di SONG

Kexin XI

Xiaoting XIE

Xiaoyan WU

Wei ZHAO

Yicong LIN

Yue WANG

Related Institution

BSL-3 Laboratory(Guangdong), Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health, Southern Medical University

Department of Molecular Diagnostics, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine

Department of Pathology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University

Department of Oncology, Peking University International Hospital

Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University

AI问答

⁰